The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant

Maria Rendina, Antonio Schena, Nicola Maurizio Castellaneta, Francesco Losito, Anna Cinzia Amoruso, Giovanni Stallone, Francesco Paolo Schena, Alfredo Di Leo, Antonio Francavilla

Research output: Contribution to journalArticlepeer-review

Abstract

Background/Aims: We undertook a pilot study to investigate the efficacy and safety of peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed chronic HCV patients awaiting renal transplant. Methods: Patients received peginterferon alfa-2a 135 μg/week plus ribavirin 200 mg/day for 24 or 48 weeks (genotype non-1 and 1, respectively). The dose of ribavirin was tailored according to plasma concentrations and to haemoglobin levels. Outcomes in treated patients were compared with those of a matched untreated control group. Results: Thirty-five patients received treatment, while 35 served as untreated controls. Thirty patients completed treatment; patients were withdrawn due to transplantation (n = 2), severe anaemia (n = 1), dermatitis (n = 1) and non-response (n = 1) resulting in a drop-out rate of 14%. Overall, 34/35 treated patients were HCV RNA negative at week 4 and had undetectable RNA at the end of treatment, compared with none of the untreated controls (ETR 97% vs 0%; p <0.001). Moreover, all achieved sustained virological response after 24 weeks of treatment-free follow-up versus no control patients (SVR 97% vs 0 %; p <0.001). Conclusions: In this study, we have shown for the first time in a large cohort of patients that HCV-patients on haemodialysis can be treated successfully with peginterferon alfa-2a (40 kDa) plus ribavirin.

Original languageEnglish
Pages (from-to)768-774
Number of pages7
JournalJournal of Hepatology
Volume46
Issue number5
DOIs
Publication statusPublished - May 2007

Keywords

  • Haemodialysis
  • HCV
  • Hepatitis
  • Kidney
  • Peginterferon
  • Ribavirin
  • Transplant

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant'. Together they form a unique fingerprint.

Cite this